A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

Summary

This study is to assess the efficacy, safety, and tolerability of the investigational drug UCB0942in adult subjects with drug-resistant focal epilepsy across multiple centers in Europe.

Timeline

Start

2015-07

Primary completion

2017-02

Completion

2017-07

Outcome

Missed primary endpoint

registry analysis (superiority test); Placebo/UCB0942 (FAS) vs UCB0942/UCB0942 (FAS); p =0.0679; Odds Ratio (OR) 4.14 (95% CI 0.90 to 19.06); Regression, Logistic NCT02495844 ↗

Drugs

Indications